Cart
sales@molnova.com
PSB-15160
CAS No. 215997-93-6
PSB-15160( —— )
Catalog No. M36312 CAS No. 215997-93-6
PSB-15160 is a compound that inhibits the growth of MCF7 (breast), NCI-H460 (lung) and SF-268 (NCS) cells in the treatment of estrogen-dependent tumours.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 418 | In Stock |
|
| 10MG | 616 | In Stock |
|
| 25MG | 938 | In Stock |
|
| 50MG | 1293 | In Stock |
|
| 100MG | 1739 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NamePSB-15160
-
NoteResearch use only, not for human use.
-
Brief DescriptionPSB-15160 is a compound that inhibits the growth of MCF7 (breast), NCI-H460 (lung) and SF-268 (NCS) cells in the treatment of estrogen-dependent tumours.
-
DescriptionPSB-15160 is a compound that inhibits the growth of MCF7 (breast), NCI-H460 (lung) and SF-268 (NCS) cells in the treatment of estrogen-dependent tumours.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number215997-93-6
-
Formula Weight282.29
-
Molecular FormulaC17H12F2N2
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESC(C=1C=2C(NC1)=CC=C(F)C2)C=3C=4C(NC3)=CC=C(F)C4
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
trans-isrib A17
trans-isrib A17 (ISR-IN-1) is an potent inhibitor of the integrated stress response with EC50 of 0.6 nM.
-
ShK-Dap22
Extremely potent KV1.3 channel blocker (Kd = 23 pM for mKV1.3 currents). Selective for KV1.3 over other mammalian potassium channels (IC50 values are 23, 1800, 10500, 37000 and 39000 pM for mKV1.3, mKV1.1, hKV1.6, mKV1.4 and rKV1.2 respectively, and >100000 pM for hKV1.5, mKV1.7, hKV3.1, rKV3.4 and hKCa4). Suppresses T cell activation in vitro (IC50 < 500 pM).
-
GRGDSP TFA
GRGDSP, a synthetic linear RGD peptide, is an integrin inhibitor which can be used to modify the surface of cardiovascular implants such as vascular grafts to promote endothelialization.
